Bicara Therapeutics (BCAX) Depreciation & Amortization (CF) (2023 - 2026)
Bicara Therapeutics (BCAX) reported Depreciation & Amortization (CF) of $44000.0 for Q1 2026, up 131.58% on a YoY basis from $19000.0 in Q1 2025, and up 2.33% quarter-over-quarter from $43000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Bicara Therapeutics has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $44000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 131.58% year-over-year to $44000.0; the trailing twelve-month figure through Mar 2026 stood at $130000.0 (up 109.68% YoY), and the FY2025 full-year result was $105000.0, up 87.5% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $44000.0, up from $43000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $44000.0 in Q1 2026, with the low at $13000.0 in Q1 2024.
- Historically, Depreciation & Amortization (CF) has averaged $21900.0 across 4 years, with a median of $17000.0 in 2024.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) increased 7.14% — and 2025, when it surged 186.67%.
- Bicara Therapeutics' Depreciation & Amortization (CF) stood at $14000.0 in 2023, then increased by 7.14% to $15000.0 in 2024, then surged by 186.67% to $43000.0 in 2025, then grew by 2.33% to $44000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $44000.0 (Q1 2026), $43000.0 (Q4 2025), and $24000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Bicara Therapeutics | 1.41 Bn | 1.41 Bn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |